⚠ Evidence warning: Clinical trials or other evidence do not support the claims that N-acetylcysteine, glycine and methylation cofactors improve chronic fatigue, fibromyalgia and Hashimoto's thyroiditis and support heavy-metal or mold detox. This page keeps it as a report of what people, websites or other media say.
Sulfur for Glutathione and Methylation
Two of the most fundamental biochemical economies of the human body — the antioxidant defense system anchored by glutathione and the universal methyl-donation system anchored by S-adenosylmethionine (SAMe) — converge on a single dietary requirement: adequate sulfur. The sulfur amino acids methionine and cysteine feed both pathways simultaneously, linked through the trans-sulfuration arm of the methionine cycle and gated by the enzyme cystathionine beta-synthase (CBS). When methylenetetrahydrofolate reductase (MTHFR) variants slow the folate cycle, when B12 status drops, or when oxidative stress acutely depletes glutathione, the methylation system and the antioxidant system both falter together. This deep-dive walks through the cysteine-to-glutathione synthesis pathway, the S-adenosylmethionine-to-S-adenosylhomocysteine (SAH)-to-homocysteine methylation cycle, the trans-sulfuration bridge that connects them, the MTHFR/CBS bottlenecks that cause real-world dysfunction, and the practical use of N-acetylcysteine (NAC), methionine, glycine, B12, folate, and B6 as cofactors that keep the whole system running.
Table of Contents
- Two Systems, One Substrate
- Cysteine and Methionine: The Sulfur Amino Acids
- Glutathione Synthesis: Two Enzymes, and Cysteine as Rate-Limit
- The Methylation Cycle: SAM, SAH, and Homocysteine
- The Trans-Sulfuration Pathway: Homocysteine to Cysteine via CBS
- The Methylenetetrahydrofolate Reductase-SAMe-Glutathione Axis
- N-Acetylcysteine as Cysteine Donor
- Clinical Applications
- Cautions and Cofactor Balance
- Key Research Papers
- Connections
- Featured Videos
Two Systems, One Substrate
The antioxidant defense system and the methylation system are usually taught as two unrelated topics. They are not. They share a substrate (sulfur amino acids), a regulatory bottleneck (the enzyme cystathionine beta-synthase), and a clinical implication: depletion of one tends to deplete the other.
The methionine cycle takes dietary methionine, converts it to S-adenosylmethionine (the universal methyl donor used in over 200 reactions), and on demethylation produces SAH and then homocysteine. Homocysteine has two fates: remethylation back to methionine (the folate cycle, dependent on B12 and methylenetetrahydrofolate reductase-derived 5-methyltetrahydrofolate) or commitment to the trans-sulfuration pathway (irreversible, dependent on B6 and cystathionine beta-synthase). The trans-sulfuration pathway converts homocysteine to cystathionine, then to cysteine, and the cysteine feeds glutathione synthesis.
This single connection has enormous clinical consequences. When methylation demand is high (chronic infection, detoxification of xenobiotics, neurotransmitter synthesis), more methionine cycles through to homocysteine, more homocysteine commits to trans-sulfuration, and more cysteine is available for glutathione synthesis — the system upregulates antioxidant capacity in step with methylation demand. Conversely, when methionine intake is marginal, when B6/B12/folate are deficient, or when methylenetetrahydrofolate reductase variants slow the cycle, both systems suffer in parallel.
Cysteine and Methionine: The Sulfur Amino Acids
The body has two sulfur-bearing amino acids: methionine (essential, must be obtained from diet) and cysteine (conditionally essential, can be synthesized from methionine via trans-sulfuration, and is also sold as a supplement).
- Methionine — an essential amino acid (humans cannot synthesize it). It serves as the initiator amino acid for almost all protein translation (initiator Met-tRNA) and as the primary dietary source of sulfur in the methionine cycle. Rich sources: eggs, meat, fish, dairy, Brazil nuts, sesame seeds, legumes.
- Cysteine — conditionally essential. Its thiol (-SH) functional group is uniquely reactive, enabling disulfide bond formation (the cross-links that fold and stabilize proteins like insulin, antibodies, keratin) and providing the redox-active site of glutathione. Direct dietary sources: eggs, poultry, garlic, onions, cruciferous vegetables, legumes, yogurt. Supplemental form: N-acetylcysteine.
- Taurine — a sulfur-containing beta-amino acid derived from cysteine via cysteine sulfinic acid decarboxylase. Functions in bile acid conjugation, cell membrane stabilization, calcium signaling, and osmoregulation. See our Taurine page.
- Homocysteine — the demethylated intermediate of the methionine cycle. Not used in protein synthesis. Either remethylated to methionine (folate/B12-dependent) or committed to trans-sulfuration (B6-dependent). Elevated serum homocysteine is a marker of dysfunction in either pathway — see our Homocysteine page.
- Glutathione (reduced glutathione, GSH) — a tripeptide (gamma-glutamyl-cysteinyl-glycine) whose redox-active cysteine residue is the cellular currency of antioxidant defense.
Glutathione Synthesis: Two Enzymes, and Cysteine as Rate-Limit
Glutathione is synthesized in a two-step cytosolic pathway from three precursor amino acids: glutamate, cysteine, and glycine. The reactions are catalyzed by two enzymes:
- Glutamate-cysteine ligase (GCL), also called gamma-glutamylcysteine synthetase, joins glutamate to cysteine via an unusual gamma-peptide bond (connecting glutamate's gamma-carboxyl to cysteine's amino group, rather than the standard alpha-carboxyl). This is the rate-limiting step of glutathione synthesis. GCL is a heterodimer of catalytic (GCLC) and modifier (GCLM) subunits, transcriptionally induced by oxidative stress through the Nrf2/Keap1/ARE pathway, and feedback-inhibited by glutathione itself.
- Glutathione synthetase (GS) adds glycine to the dipeptide, completing the tripeptide. GS is not normally rate-limiting.
The supply of cysteine is the major determinant of the rate of glutathione synthesis under most physiological conditions. Cellular cysteine pools are kept low (cysteine is toxic at high concentration because of its high redox activity and metal-binding promiscuity), so any acute increase in glutathione demand — acetaminophen overdose, ischemia-reperfusion, viral infection — rapidly depletes the available cysteine and limits the synthesis response.
This is the entire pharmacological rationale for N-acetylcysteine. N-acetylcysteine bypasses the slow membrane transport of free cysteine, delivers cysteine intracellularly within an hour of oral or intravenous (IV) dosing, and rapidly restores glutathione synthesis capacity. The intravenous protocol for acetaminophen overdose (loading dose 150 mg/kg, then maintenance) was developed in the 1970s by Prescott in Edinburgh and has become standard worldwide.
Glycine is the secondary rate-limiting substrate (often overlooked). Many adults consume marginal glycine, and the resulting modest restriction limits glutathione recovery after oxidative stress. Practitioners describe adding glycine at 5-15 g/day to N-acetylcysteine protocols, particularly for older adults — the "GlyNAC" combination popularized by Sekhar at Baylor has shown striking improvements in oxidative stress markers and mitochondrial function in trials.
The study that started this line of work (Sekhar and colleagues, 2011) compared 8 older adults with 8 younger adults. The older group had about half the glutathione in their red blood cells (1.12 versus 2.08 mmol per litre of red cells), made it much more slowly, and had higher markers of oxidative stress and oxidant damage. After two weeks of supplements of the glutathione building blocks cysteine and glycine, the older adults’ glutathione was 94.6% higher, its fractional synthesis rate 78.8% higher and its absolute synthesis rate 230.9% higher, and their oxidative-stress markers fell to levels no different from the younger adults.
The Methylation Cycle: SAM, SAH, and Homocysteine
The methionine cycle is the engine that generates methyl groups for hundreds of cellular reactions. The cycle has four obligate steps:
- Methionine + adenosine triphosphate (ATP) → SAM — methionine adenosyltransferase (MAT) attaches an adenosyl group to methionine's sulfur, generating S-adenosylmethionine (SAMe), the universal methyl donor.
- SAM → SAH — methyltransferases transfer SAM's methyl group to substrates (DNA, histones, neurotransmitters, phospholipids, creatine), producing S-adenosylhomocysteine (SAH). There are over 200 distinct methyltransferases in the human genome.
- SAH → homocysteine + adenosine — SAH hydrolase splits SAH into homocysteine and adenosine. This step is reversible (and SAH itself is a potent inhibitor of methyltransferases), making the SAM/SAH ratio the cellular regulator of methylation status.
- Homocysteine → methionine (remethylation) — methionine synthase (MS) uses methylcobalamin (B12) as cofactor and 5-methyltetrahydrofolate (from the folate cycle, dependent on methylenetetrahydrofolate reductase) as methyl donor to regenerate methionine. Alternatively, betaine-homocysteine methyltransferase (BHMT) uses betaine (trimethylglycine) as methyl donor in liver and kidney.
S-adenosylmethionine's two hundred-plus methyltransferase substrates include:
- DNA methylation (the DNA methyltransferases DNMT1, DNMT3A, DNMT3B) — the dominant epigenetic mark, controlling gene expression and cellular differentiation
- Histone methylation (lysine and arginine methyltransferases) — the histone mark with the broadest combinatorial code in epigenetics
- Neurotransmitter synthesis — the final methylation step in epinephrine synthesis (phenylethanolamine N-methyltransferase, PNMT), methylation of dopamine and serotonin precursors
- Phospholipid synthesis — phosphatidylethanolamine N-methyltransferase (PEMT) methylates phosphatidylethanolamine to phosphatidylcholine, essential for very-low-density lipoprotein (VLDL) secretion and bile production
- Creatine synthesis — guanidinoacetate N-methyltransferase (GAMT) methylates guanidinoacetate to creatine, the largest single S-adenosylmethionine consumer in the body
- Catechol-O-methyltransferase (COMT) — methylates catecholamines and catechol estrogens, a major detoxification pathway
- Histamine N-methyltransferase — the central inactivator of histamine
Each of these methylation reactions also produces SAH. SAH inhibits the very methyltransferases that produce it — making efficient SAH clearance (via SAH hydrolase and subsequent disposal of homocysteine) the rate-limiting step for methylation broadly. The SAM:SAH ratio is the cellular "methylation index," and a high ratio favors methylation while a low ratio inhibits it.
The Trans-Sulfuration Pathway: Homocysteine to Cysteine via CBS
The methionine cycle has only two exits for homocysteine: remethylation back to methionine, or commitment to the trans-sulfuration pathway. The choice is regulated by S-adenosylmethionine concentration — high S-adenosylmethionine (indicating methionine abundance) allosterically activates cystathionine beta-synthase (CBS) and commits homocysteine to trans-sulfuration, while low S-adenosylmethionine leaves CBS inactive and homocysteine recycles to methionine.
The trans-sulfuration pathway has two enzymes, followed by the onward fates of the cysteine it makes:
- Cystathionine beta-synthase (CBS) — condenses homocysteine and serine to form cystathionine, with elimination of water. Requires pyridoxal-5-phosphate (active vitamin B6) as cofactor. The rate-limiting and committing step. Allosterically activated by S-adenosylmethionine (sensing methionine abundance). CBS loss-of-function mutations cause classical homocystinuria (severe hyperhomocysteinemia, dislocated ocular lens, vascular thrombosis, marfanoid habitus). CBS upregulation (gain-of-function variants) is a topic of debate in the functional medicine literature — some practitioners attribute "sulfur intolerance" symptoms to CBS hyperactivity, though the evidence is largely anecdotal.
- Cystathionine gamma-lyase (CGL/CSE) — cleaves cystathionine to cysteine, alpha-ketobutyrate, and ammonia. Also requires pyridoxal-5-phosphate.
- After trans-sulfuration: cysteine’s fates, ending in sulfite-to-sulfate oxidation — this step lies downstream of trans-sulfuration, in cysteine breakdown. The cysteine that exits the trans-sulfuration pathway has multiple fates: incorporation into glutathione (the largest sink), incorporation into protein synthesis, oxidation to taurine via cysteine sulfinic acid, or further oxidation to inorganic sulfate (SO42-) for sulfation reactions that use 3′-phosphoadenosine-5′-phosphosulfate (PAPS). The final cysteine-to-sulfate oxidation is catalyzed by sulfite oxidase, a molybdenum-dependent enzyme — one of the unexpected connections between trace minerals and sulfur metabolism.
The trans-sulfuration enzymes also produce hydrogen sulfide (H2S), a gas signalling molecule (gasotransmitter), from CBS and CGL action on cysteine, plus ammonia as a by-product. H2S at low endogenous concentrations is a signaling molecule with vasodilator and cytoprotective properties — the same gas that is toxic at high concentrations is a normal cellular messenger at nanomolar levels. See the Detoxification page for more on H2S gasotransmitter signaling.
The Methylenetetrahydrofolate Reductase-SAMe-Glutathione Axis
Methylenetetrahydrofolate reductase (MTHFR) is the enzyme that converts 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate — the form of folate that donates a methyl group to homocysteine in the methionine synthase reaction. The C677T variant (encoding an alanine-to-valine substitution at position 222) reduces enzyme activity by approximately 35% in heterozygotes and 70% in homozygotes. The A1298C variant has milder effects. Roughly 10-15% of populations of European ancestry are C677T homozygotes; the frequency varies considerably by region.
The 1995 study that first described this common variant (Frosst and colleagues) found it on about 38% of chromosomes in unselected people. Carrying one or two copies went with lower enzyme activity and an enzyme that breaks down with heat (thermolabile) in white-blood-cell extracts, and people carrying two copies had significantly higher blood homocysteine.
The downstream effects of reduced methylenetetrahydrofolate reductase activity:
- Reduced 5-methylTHF — less methyl-folate available for methionine synthase, so less efficient remethylation of homocysteine back to methionine. Result: elevated serum homocysteine.
- Reduced S-adenosylmethionine — less methionine regenerated means less S-adenosylmethionine synthesized, slowing all 200+ methylation reactions.
- Compensatory shift to trans-sulfuration — chronically elevated homocysteine drives more flux through CBS to the trans-sulfuration pathway. This generates more cysteine and supports more glutathione synthesis — until the system can't compensate further.
- Eventual glutathione depletion — if dietary methionine is marginal, or if B6 deficiency limits CBS function, the compensatory trans-sulfuration upregulation fails, homocysteine continues to rise, and both S-adenosylmethionine-dependent methylation and cysteine-dependent glutathione synthesis suffer simultaneously.
The practice view: practitioners who work with methylenetetrahydrofolate reductase variants describe supporting both sides — methylfolate (which bypasses the slow methylenetetrahydrofolate reductase step), adequate methionine intake, B6/B12 cofactors, and often N-acetylcysteine as a direct cysteine source. In this view, folate alone addresses only the methylation side, not the half of the problem that lives on the glutathione side.
The methylated form of folate (5-methyltetrahydrofolate, also called L-methylfolate or 5-MTHF) is sold as calcium or glucosamine salts; practitioners describe 400-1000 mcg/day. Methylcobalamin (B12) is the corresponding active form for methionine synthase, described at 500-1000 mcg/day under the tongue. Pyridoxal-5-phosphate (P5P, active B6) is the cofactor for CBS and CGL, described at 25-50 mg/day. Together these "methylation cofactors" are what practitioners commonly use for methylenetetrahydrofolate reductase-related concerns.
N-Acetylcysteine as Cysteine Donor
N-acetylcysteine is an acetylated derivative of cysteine that crosses cell membranes far more efficiently than free cysteine, is hydrolyzed intracellularly to free cysteine and acetate, and delivers cysteine to the glutathione synthesis pathway within an hour of oral or intravenous administration. N-acetylcysteine is the clinical workhorse for restoring glutathione status acutely or chronically.
- Acetaminophen overdose — its best-known emergency use. N-acetylcysteine was first used as a mucus-thinning (mucolytic) drug; Prescott’s first report of intravenous N-acetylcysteine for acetaminophen poisoning came in 1977. N-acetylcysteine restores hepatic glutathione, allowing conjugation and clearance of the toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI). Intravenous protocol: 150 mg/kg loading dose, then maintenance over 21 hours. Survival benefit if administered within 8 hours of overdose; still beneficial up to 24 hours.
- Chronic obstructive pulmonary disease (COPD) — oral N-acetylcysteine 600-1200 mg twice daily reduces exacerbation frequency in moderate-to-severe chronic obstructive pulmonary disease, particularly in patients not on inhaled corticosteroids. Mucolytic action (N-acetylcysteine cleaves disulfide bonds in mucus) plus systemic glutathione restoration.
- Polycystic ovary syndrome (PCOS) and fertility — N-acetylcysteine 1200-1800 mg/day improves insulin sensitivity, hyperandrogenism, and ovulation rates in polycystic ovary syndrome. Multiple randomized controlled trials (RCTs) support adjunctive use with clomiphene for ovulation induction.
- Psychiatric applications — emerging evidence for N-acetylcysteine in obsessive-compulsive disorder, trichotillomania, gambling disorder, and bipolar depression. Doses 1200-2400 mg/day. Mechanism likely combines glutathione restoration in stressed neurons and cysteine-mediated modulation of glutamate.
- Acute respiratory infection — older European data (De Flora et al. 1997): in a randomised, double-blind trial of 262 people (78% aged 65 or over), N-acetylcysteine 600 mg twice daily for 6 months significantly reduced the frequency and severity of influenza-like episodes and the time spent in bed. Infection rates with the circulating influenza strain were similar in both groups, but only 25% of infected people on N-acetylcysteine developed symptoms, against 79% on placebo, and cell-mediated immunity shifted significantly from a weak (anergic) to a normal response.
- Bioavailability — practitioners commonly describe taking N-acetylcysteine on an empty stomach or with vitamin C, on the view that food reduces absorption. Some people report tolerating higher doses better when split (600 mg three times daily rather than 1800 mg once).
For a full clinical treatment of N-acetylcysteine's applications, see our N-acetylcysteine main page.
Clinical Applications
- Acetaminophen overdose — intravenous N-acetylcysteine remains the standard antidote worldwide, the original demonstration that direct cysteine support can rescue acutely failing glutathione synthesis.
- Mitochondrial dysfunction in aging — GlyNAC (glycine 1.33 mmol/kg/day plus cysteine 0.81 mmol/kg/day given as N-acetylcysteine, the doses in the 2021 pilot’s full text) improved oxidative stress markers, mitochondrial function, insulin sensitivity, gait speed, and cognitive function in older adults in Sekhar’s Baylor studies: a 24-week open-label pilot in 8 older adults (with 8 young adults studied once for comparison), whose benefits declined after GlyNAC was stopped for 12 weeks, and a 16-week randomised placebo-controlled trial in 24 older adults.
- The 2023 GlyNAC trial — in this randomised trial, 12 older adults took GlyNAC and 12 took a look-alike amino acid (alanine) as placebo for 16 weeks. GlyNAC, and not placebo, improved or corrected low glutathione, oxidative stress, mitochondrial dysfunction (including fat-burning in the mitochondria), inflammation, blood-vessel lining (endothelial) function, insulin resistance, several hallmarks of aging, gait speed, muscle strength, waist size and systolic blood pressure; it was safe and well tolerated. It is still a small trial.
- Hyperhomocysteinemia — practitioners describe methylation cofactor support (methylfolate, methyl-B12, P5P) for the remethylation side and adequate methionine intake plus B6 for the trans-sulfuration side, aiming to address both halves of homocysteine clearance.
- Detoxification protocols — practitioners use N-acetylcysteine, glycine, methionine, and methylation cofactors to support phase II conjugation pathways (sulfation and glutathione conjugation simultaneously) during heavy-metal chelation or post-mold-exposure recovery.
- Hashimoto's thyroiditis — selenium plus N-acetylcysteine supports glutathione peroxidase activity in thyroid tissue, where chronic oxidative stress drives autoimmune progression. Selenium 200 mcg/day plus N-acetylcysteine 600-1200 mg/day is a common adjunct in practitioners’ protocols.
- Chronic fatigue and fibromyalgia — many patients have low whole-blood glutathione and elevated oxidative stress markers. Practitioners report that N-acetylcysteine, glycine, methylation cofactor support, and dietary sulfur amino acid optimization frequently improve symptoms when conventional therapy has plateaued.
- Pre-conception and pregnancy — methylation is fundamental to fetal development. Practitioners emphasise folate (many prefer methylfolate for people with methylenetetrahydrofolate reductase variants), B12, choline, glycine, and adequate methionine before conception and through pregnancy.
Cautions and Cofactor Balance
- Methionine excess — very high methionine intake (such as from large doses of whey protein or methionine-rich protein powders) can drive homocysteine elevation in patients with inadequate B6/B12/folate or methylenetetrahydrofolate reductase variants. The methylation cofactors above are the ones that clear homocysteine.
- N-acetylcysteine and sulfur intolerance — a small subset of patients report symptoms (headache, brain fog, sulfur-smelling sweat or urine) when starting N-acetylcysteine. The mechanism is debated — possibly CBS upregulation, possibly hydrogen sulfide overproduction. One practice some practitioners describe is starting at 300 mg/day and raising the dose by 300 mg per week.
- B12 deficiency masked by folate — high-dose folate can normalize hematologic indices in B12 deficiency without correcting the underlying neurological deficit. For this reason B12 status (and methylmalonic acid as a functional marker) is commonly checked before high-dose folate supplementation.
- Niacin and methylation — high-dose niacin (used for lipid management) consumes S-adenosylmethionine methyl groups during its hepatic methylation to N-methylnicotinamide. Practitioners describe adding betaine or additional methylation cofactors during chronic high-dose niacin use.
- L-methylfolate and bipolar disorder — case reports describe activation of mania with high-dose L-methylfolate in bipolar patients; these reports concern people with a history of bipolar disorder.
- Schizophrenia and methylation — methylation status interacts with schizophrenia symptomatology in complex ways. How major changes to methylation support affect people with serious mental illness is not well understood.
- Pregnancy — N-acetylcysteine is sometimes used in pregnancy (acetaminophen overdose protocol, some polycystic ovary syndrome protocols) but there is no good safety data on routine high-dose supplementation in pregnancy. Methylfolate, methyl-B12, and choline are well-established pregnancy supplements.
This content is provided for informational purposes only and does not constitute medical advice. The key safety facts on this page: high-dose folate can hide the nerve damage of B12 deficiency, and case reports describe mania with high-dose L-methylfolate in people with bipolar disorder.
Key Research Papers
- Mosharov E, Cranford MR, Banerjee R. (2000). The quantitatively important relationship between homocysteine metabolism and glutathione synthesis by the transsulfuration pathway and its regulation by redox changes. Biochemistry. — PubMed PMID: 11041866
- Vitvitsky V, Thomas M, Ghorpade A, Gendelman HE, Banerjee R. (2006). A functional transsulfuration pathway in the brain links to glutathione homeostasis. Journal of Biological Chemistry. — PubMed PMID: 17005561
- Prescott LF, Park J, Ballantyne A, Adriaenssens P, Proudfoot AT. (1977). Treatment of paracetamol (acetaminophen) poisoning with N-acetylcysteine. The Lancet. — PubMed PMID: 70646
- Sekhar RV, Patel SG, Guthikonda AP, et al. (2011). Deficient synthesis of glutathione underlies oxidative stress in aging and can be corrected by dietary cysteine and glycine supplementation. American Journal of Clinical Nutrition. — PubMed PMID: 21795440
- Kumar P, Liu C, Hsu JW, Chacko S, Minard C, Jahoor F, Sekhar RV. (2021). Glycine and N-acetylcysteine (GlyNAC) supplementation in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, insulin resistance, endothelial dysfunction, genotoxicity, muscle strength, and cognition: Results of a pilot clinical trial. Clinical and Translational Medicine. — PubMed PMID: 33783984
- Kumar P, Liu C, Suliburk J, et al. (2023). Supplementing Glycine and N-Acetylcysteine (GlyNAC) in Older Adults Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Physical Function, and Aging Hallmarks: A Randomized Clinical Trial. The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences. — PubMed PMID: 35975308
- Frosst P, Blom HJ, Milos R, et al. (1995). A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genetics. — PubMed PMID: 7647779
- Selhub J. (1999). Homocysteine metabolism. Annual Review of Nutrition. — PubMed PMID: 10448523
- Lu SC. (2009). Regulation of glutathione synthesis. Molecular Aspects of Medicine. — PubMed PMID: 18601945
- De Flora S, Grassi C, Carati L. (1997). Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment. European Respiratory Journal. — PubMed PMID: 9230243
- Atkuri KR, Mantovani JJ, Herzenberg LA, Herzenberg LA. (2007). N-Acetylcysteine: a safe antidote for cysteine/glutathione deficiency. Current Opinion in Pharmacology. — PubMed PMID: 17602868
- Stipanuk MH. (2004). Sulfur amino acid metabolism: pathways for production and removal of homocysteine and cysteine. Annual Review of Nutrition. — PubMed PMID: 15189131
- Banerjee R, Zou CG. (2005). Redox regulation and reaction mechanism of human cystathionine-beta-synthase: a PLP-dependent hemesensor protein. Archives of Biochemistry and Biophysics. — PubMed PMID: 15581573
PubMed Topic Searches
Connections
- All Minerals
- Sulfur (Main Page)
- Sulfur Benefits Hub
- Sulfur for Joint Health
- Sulfur for Skin Health
- Sulfur for Detoxification
- N-Acetylcysteine
- Glutathione
- Cysteine
- Methionine
- Glycine
- Taurine
- Homocysteine
- Molybdenum (Sulfite Oxidase)
- Selenium (Glutathione Peroxidase)
- Oxidative Stress
- Heavy Metals
- Deficiency
- Toxicity
- History